193 related articles for article (PubMed ID: 11953478)
21. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
Martínez E; Arnaiz JA; Podzamczer D; Dalmau D; Ribera E; Domingo P; Knobel H; Riera M; Pedrol E; Force L; Llibre JM; Segura F; Richart C; Cortés C; Javaloyas M; Aranda M; Cruceta A; de Lazzari E; Gatell JM;
N Engl J Med; 2003 Sep; 349(11):1036-46. PubMed ID: 12968087
[TBL] [Abstract][Full Text] [Related]
22. Salvage therapy studies.
Proj Inf Perspect; 1998 Sep; (25):7. PubMed ID: 11365850
[TBL] [Abstract][Full Text] [Related]
23. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
[TBL] [Abstract][Full Text] [Related]
24. Antiretroviral rounds. A very discordant response.
Henry K; Jenny-Avital E
AIDS Clin Care; 2002 Jan; 14(1):4-5, 8. PubMed ID: 11802628
[No Abstract] [Full Text] [Related]
25. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
Bickel M; Rickerts V; Stephan C; Jacobi V; Rottmann C; Dauer B; Carlebach A; Thalhammer A; Miller V; Staszweski S
HIV Med; 2005 May; 6(3):179-84. PubMed ID: 15876284
[TBL] [Abstract][Full Text] [Related]
26. Experience with efavirenz in end-stage renal disease.
Das S; Ghanem M; Huengsberg M
Int J STD AIDS; 2004 Feb; 15(2):143. PubMed ID: 15006080
[No Abstract] [Full Text] [Related]
27. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694
[No Abstract] [Full Text] [Related]
28. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
29. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B
Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962
[TBL] [Abstract][Full Text] [Related]
30. I want a new drug. An overview of three new anti-HIV drugs.
Simmons P
Res Initiat Treat Action; 1998 Jun; 4(3):9-11. PubMed ID: 11365539
[TBL] [Abstract][Full Text] [Related]
31. New drugs in development.
Proj Inf Perspect; 1998 Sep; (25):8. PubMed ID: 11365851
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of the combination of efavirenz and abacavir in HIV-infected patients failing antiretroviral therapy.
Tenorio AR; Irlanda IE; Narkiewicz E; Smith KY; Kessler HA; Sha BE
AIDS; 2000 Jul; 14(10):1470-1. PubMed ID: 10930173
[No Abstract] [Full Text] [Related]
33. Protease inhibitor failure trial: combination 1592, 141W94, and efavirenz.
AIDS Treat News; 1997 Dec; (No 284):4. PubMed ID: 11364914
[TBL] [Abstract][Full Text] [Related]
34. Treatment of the naive patient.
Bartlett JG
Hopkins HIV Rep; 1999 Mar; 11(2):1, 10-1. PubMed ID: 11366244
[TBL] [Abstract][Full Text] [Related]
35. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study.
Friedl AC; Ledergerber B; Flepp M; Hirschel B; Telenti A; Furrer H; Bucher HC; Bernasconi E; Weber R;
AIDS; 2001 Sep; 15(14):1793-800. PubMed ID: 11579241
[TBL] [Abstract][Full Text] [Related]
36. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
37. The use of efavirenz as a part of late rescue antiretroviral treatment.
Manfredi R; Rizzo E; Calza L; Chiodo F
HIV Clin Trials; 2001; 2(5):413-20. PubMed ID: 11673816
[TBL] [Abstract][Full Text] [Related]
38. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
[TBL] [Abstract][Full Text] [Related]
39. Switch to efavirenz in a protease inhibitor-containing regimen.
Knechten H; Stürner KH; Höhn C; Braun P
HIV Clin Trials; 2001; 2(3):200-4. PubMed ID: 11590528
[TBL] [Abstract][Full Text] [Related]
40. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
Wolbach J; Capoccia K
Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
